<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01004614</url>
  </required_header>
  <id_info>
    <org_study_id>A0531088</org_study_id>
    <nct_id>NCT01004614</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study For 5 Mg Amlodipine Orally-Disintegrating Tablet</brief_title>
  <official_title>An Open, Randomized, Parallel-Cohort, 2-Periods, Crossover, Single Dose Bioequivalence Study For 5 Mg Amlodipine Orally-Disintegrating Tablet In Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to determine if 5 mg amlodipine 3rd Orally-Disintegrating (OD)
      tablet (new formulation) and 5 mg amlodipine 2nd OD tablet (commercial formulation) are
      bioequivalent.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve From Zero Time Until the Last Sampling Time (AUCt)</measure>
    <time_frame>prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose</time_frame>
    <description>Area under the concentration-time curve from zero time until the last sampling time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast), Area Under the Plasma Concentration-Time Curve to Infinity (AUCinf)</measure>
    <time_frame>prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose</time_frame>
    <description>AUC last = Area under the concentration versus time curve from zero time until the last measurable concentration is calculated using the trapezoidal rule.
AUCinf = AUClast + (Ct / kel), where Ct is the estimated concentration at the last measurable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Elimination Phase Rate Constant (Kel)</measure>
    <time_frame>prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose</time_frame>
    <description>Estimated as the absolute value of the slope of a linear regression during the terminal phase of the natural-logarithm (ln) transformed concentration-time profile.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Elimination Half-Life (T-half)</measure>
    <time_frame>prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose</time_frame>
    <description>Terminal phase half-life calculated as ln(2) / kel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time (MRT)</measure>
    <time_frame>prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose</time_frame>
    <description>MRT = AUMCinf / AUCinf, where AUMCinf is the area under the first moment curve from zero time to infinity calculated as AUMCinf = AUMCt + ((t x Ct) / kel) + (Ct / kel^2). AUMCt is the area under the first moment curve from zero time to time t calculated using the trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 subjects (12 subjects per sequence) will receive treatment A) one 5 mg amlodipine 3rd OD tablet (test) with water and treatment B) one 5 mg amlodipine 2nd OD tablet (reference) with water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24 subjects (12 subjects per sequence) will receive treatment C) one 5 mg amlodipine 3rd OD tablet (test) without water, and treatment D) one 5 mg amlodipine 2nd OD tablet (reference) without water</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>3rd OD 5 mg tablet single oral dose administered with water</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>2nd OD 5 mg tablet single oral dose administered with water</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>3rd OD 5 mg tablet single oral dose administered without water</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>2nd OD 5 mg tablet single oral dose administered without water</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy;

          -  Body Mass Index (BMI) of 18 to 28 kg/m2;

          -  total body weight within the range of 50 to 100 kg

        Exclusion Criteria:

          -  History of regular alcohol consumption exceeding 14 drinks/week

          -  Use of tobacco- or nicotine-containing products in excess of the equivalent of 10
             cigarettes per day
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0531088&amp;StudyName=Bioequivalence%20Study%20For%205%20Mg%20Amlodipine%20Orally-Disintegrating%20Tablet</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2009</study_first_submitted>
  <study_first_submitted_qc>October 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2009</study_first_posted>
  <results_first_submitted>December 3, 2010</results_first_submitted>
  <results_first_submitted_qc>November 29, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 4, 2012</results_first_posted>
  <last_update_submitted>November 29, 2011</last_update_submitted>
  <last_update_submitted_qc>November 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were screened at one center in Japan.</recruitment_details>
      <pre_assignment_details>This study consisted of 2 cohorts (I and II). The design of each cohort was an open-label, randomized, 2-periods, crossover, single-dose study in healthy adult male subjects. A washout period of at least 14 days was taken between each administration in Periods 1 and 2.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>3rd OD Tablet With Water, Then 2nd OD Tablet With Water</title>
          <description>One amlodipine third generation orally disintegrating (OD) 5 mg tablet (test) taken with water during the first intervention period, then one amlodipine second generation OD 5 mg tablet (reference) taken with water during second intervention period. A washout of 14 days was retained between periods.</description>
        </group>
        <group group_id="P2">
          <title>2nd OD Tablet With Water, Then 3rd OD Tablet With Water</title>
          <description>One amlodipine second generation OD 5 mg tablet (reference) taken with water during the first intervention period, then one amlodipine third generation OD 5 mg tablet (test) taken with water during the second intervention period. A washout of 14 days was retained between periods.</description>
        </group>
        <group group_id="P3">
          <title>3rd OD Tablet Without Water, Then 2nd OD Tablet Without Water</title>
          <description>One amlodipine third generation OD 5 mg tablet (test) taken without water during the first intervention period, then one amlodipine second generation OD 5 mg tablet (reference) taken without water during the second intervention period. A washout of 14 days was retained between periods.</description>
        </group>
        <group group_id="P4">
          <title>2nd OD Tablet Without Water, Then 3rd OD Tablet Without Water</title>
          <description>One amlodipine second generation OD 5mg tablet (reference) taken without water during the first intervention period, then one amlodipine third generation OD 5 mg tablet (test) taken without water during the second intervention period. A washout of 14 days was retained between periods.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>3rd OD Tablet With Water, Then 2nd OD Tablet With Water</title>
          <description>One amlodipine third generation orally disintegrating (OD) 5 mg tablet (test) taken with water during the first intervention period, then one amlodipine second generation OD 5 mg tablet (reference) taken with water during the second intervention period. A washout of 14 days was retained between periods.</description>
        </group>
        <group group_id="B2">
          <title>2nd OD Tablet With Water, Then 3rd OD Tablet With Water</title>
          <description>One amlodipine second generation OD 5mg tablet (reference) taken with water during the first intervention period, then one amlodipine third generation OD 5 mg tablet (test) taken with water during the second intervention period. A washout of 14 days was retained between periods.</description>
        </group>
        <group group_id="B3">
          <title>3rd OD Tablet Without Water, Then 2nd OD Tablet Without Water</title>
          <description>One amlodipine third generation OD 5 mg tablet (test) taken without water during the first intervention period, then one amlodipine second generation OD 5 mg tablet (reference) taken without water during the second intervention period. A washout of 14 days was retained between periods.</description>
        </group>
        <group group_id="B4">
          <title>2nd OD Tablet Without Water, Then 3rd OD Tablet Without Water</title>
          <description>One amlodipine second generation OD 5mg tablet (reference) taken without water during the first intervention period, then one amlodipine third generation OD 5 mg tablet (test) taken without water during the second intervention period. A washout of 14 days was retained between periods.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.8" spread="10.7"/>
                    <measurement group_id="B2" value="32.4" spread="11.1"/>
                    <measurement group_id="B3" value="37.3" spread="9.0"/>
                    <measurement group_id="B4" value="37.8" spread="12.1"/>
                    <measurement group_id="B5" value="33.1" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-Time Curve From Zero Time Until the Last Sampling Time (AUCt)</title>
        <description>Area under the concentration-time curve from zero time until the last sampling time</description>
        <time_frame>prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose</time_frame>
        <population>The PK parameter analysis set was defined as all subjects randomized and treated who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: 3rd OD Tablet (Test) With Water</title>
            <description>Cohort I: One 5 mg amlodipine 3rd OD tablet (test) taken with water as a single oral dose</description>
          </group>
          <group group_id="O2">
            <title>Cohort I: 2nd OD Tablet (Reference) With Water</title>
            <description>Cohort I: One 5 mg amlodipine 2nd OD tablet (reference) taken with water as a single oral dose</description>
          </group>
          <group group_id="O3">
            <title>Cohort II: 3rd OD Tablet (Test) Without Water</title>
            <description>Cohort II: One 5 mg amlodipine 3rd OD tablet (test) taken without water as a single oral dose</description>
          </group>
          <group group_id="O4">
            <title>Cohort II: 2nd OD Tablet (Reference) Without Water</title>
            <description>Cohort II: One 5 mg amlodipine 2nd OD tablet (reference) taken without water as a single oral dose</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From Zero Time Until the Last Sampling Time (AUCt)</title>
          <description>Area under the concentration-time curve from zero time until the last sampling time</description>
          <population>The PK parameter analysis set was defined as all subjects randomized and treated who completed the study.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.36" spread="33.16"/>
                    <measurement group_id="O2" value="129.48" spread="39.93"/>
                    <measurement group_id="O3" value="122.33" spread="32.59"/>
                    <measurement group_id="O4" value="119.75" spread="28.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Natural log transformed AUCt was analyzed using a mixed effects model with sequence, period and formulation as fixed effects and subject within sequence as a random effect. Adjusted mean difference (test - reference) and 90% CI was obtained from the model and exponentiated to provide estimates of the ratio of adjusted geometric mean and 90% CI for the ratio. Alternative hypothesis of bioequivalence: (H1: θL &lt;=µT - µR &lt;=θU); null hypothesis of inequivalence: (Ho: µT - µR &lt;θL or µT - µR &gt;θU).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence of the two formulations was concluded if the 90% confidence intervals for the ratio of adjusted geometric means for both AUCt and Cmax fell wholly within (80%, 125%).</non_inferiority_desc>
            <param_type>ratios of adjusted geometric mean</param_type>
            <param_value>98.61</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>93.09</ci_lower_limit>
            <ci_upper_limit>104.46</ci_upper_limit>
            <estimate_desc>Parameter estimate = ratio (%) (test/reference) of adjusted geometric means.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Natural log transformed AUCt was analyzed using a mixed effects model with sequence, period and formulation as fixed effects and subject within sequence as a random effect. Adjusted mean difference (test - reference) and 90% CI was obtained from the model and exponentiated to provide estimates of the ratio of adjusted geometric mean and 90% CI for the ratio. Alternative hypothesis of bioequivalence: (H1: θL &lt;=µT - µR &lt;=θU); null hypothesis of inequivalence: (Ho: µT - µR &lt;θL or µT - µR &gt;θU).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence of the two formulations was concluded if the 90% confidence intervals for the ratio of adjusted geometric means for both AUCt and Cmax fell wholly within (80%, 125%).</non_inferiority_desc>
            <param_type>ratios of adjusted geometric mean</param_type>
            <param_value>101.29</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.28</ci_lower_limit>
            <ci_upper_limit>105.45</ci_upper_limit>
            <estimate_desc>Parameter estimate = ratio (%) (test/reference) of adjusted geometric means.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax)</title>
        <time_frame>prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose</time_frame>
        <population>The PK parameter analysis set was defined as all subjects randomized and treated who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: 3rd OD Tablet (Test) With Water</title>
            <description>Cohort I: One 5 mg amlodipine 3rd OD tablet (test) taken with water as a single oral dose</description>
          </group>
          <group group_id="O2">
            <title>Cohort I: 2nd OD Tablet (Reference) With Water</title>
            <description>Cohort I: One 5 mg amlodipine 2nd OD tablet (reference) taken with water as a single oral dose</description>
          </group>
          <group group_id="O3">
            <title>Cohort II: 3rd OD Tablet (Test) Without Water</title>
            <description>Cohort II: One 5 mg amlodipine 3rd OD tablet (test) taken without water as a single oral dose</description>
          </group>
          <group group_id="O4">
            <title>Cohort II: 2nd OD Tablet (Reference) Without Water</title>
            <description>Cohort II: One 5 mg amlodipine 2nd OD tablet (reference) taken without water as a single oral dose</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax)</title>
          <population>The PK parameter analysis set was defined as all subjects randomized and treated who completed the study.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.70" spread="0.513"/>
                    <measurement group_id="O2" value="2.74" spread="0.650"/>
                    <measurement group_id="O3" value="2.48" spread="0.470"/>
                    <measurement group_id="O4" value="2.45" spread="0.409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Natural log transformed Cmax was analyzed using a mixed effects model with sequence, period and formulation as fixed effects and subject within sequence as a random effect. Adjusted mean difference (test - reference) and 90% CI was obtained from the model and exponentiated to provide estimates of the ratio of adjusted geometric mean and 90% CI for the ratio. Alternative hypothesis of bioequivalence: (H1: θL &lt;=µT - µR &lt;=θU); null hypothesis of inequivalence: (Ho: µT - µR &lt;θL or µT - µR &gt;θU).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence of the two formulations was concluded if the 90% confidence intervals for the ratio of adjusted geometric means for both AUCt and Cmax fell wholly within (80%, 125%).</non_inferiority_desc>
            <param_type>ratios of adjusted geometric mean</param_type>
            <param_value>99.30</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.28</ci_lower_limit>
            <ci_upper_limit>106.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Natural log transformed Cmax was analyzed using a mixed effects model with sequence, period and formulation as fixed effects and subject within sequence as a random effect. Adjusted mean difference (test - reference) and 90% CI was obtained from the model and exponentiated to provide estimates of the ratio of adjusted geometric mean and 90% CI for the ratio. Alternative hypothesis of bioequivalence: (H1: θL &lt;=µT - µR &lt;=θU); null hypothesis of inequivalence: (Ho: µT - µR &lt;θL or µT - µR &gt;θU).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence of the two formulations was concluded if the 90% confidence intervals for the ratio of adjusted geometric means for both AUCt and Cmax fell wholly within (80%, 125%).</non_inferiority_desc>
            <param_type>ratios of adjusted geometric mean</param_type>
            <param_value>100.84</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.93</ci_lower_limit>
            <ci_upper_limit>106.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast), Area Under the Plasma Concentration-Time Curve to Infinity (AUCinf)</title>
        <description>AUC last = Area under the concentration versus time curve from zero time until the last measurable concentration is calculated using the trapezoidal rule.
AUCinf = AUClast + (Ct / kel), where Ct is the estimated concentration at the last measurable concentration.</description>
        <time_frame>prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose</time_frame>
        <population>The PK parameter analysis set was defined as all subjects randomized and treated who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: 3rd OD Tablet (Test) With Water</title>
            <description>Cohort I: One 5 mg amlodipine 3rd OD tablet (test) taken with water as a single oral dose</description>
          </group>
          <group group_id="O2">
            <title>Cohort I: 2nd OD Tablet (Reference) With Water</title>
            <description>Cohort I: One 5 mg amlodipine 2nd OD tablet (reference) taken with water as a single oral dose</description>
          </group>
          <group group_id="O3">
            <title>Cohort II: 3rd OD Tablet (Test) Without Water</title>
            <description>Cohort II: One 5 mg amlodipine 3rd OD tablet (test) taken without water as a single oral dose</description>
          </group>
          <group group_id="O4">
            <title>Cohort II: 2nd OD Tablet (Reference) Without Water</title>
            <description>Cohort II: One 5 mg amlodipine 2nd OD tablet (reference) taken without water as a single oral dose</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast), Area Under the Plasma Concentration-Time Curve to Infinity (AUCinf)</title>
          <description>AUC last = Area under the concentration versus time curve from zero time until the last measurable concentration is calculated using the trapezoidal rule.
AUCinf = AUClast + (Ct / kel), where Ct is the estimated concentration at the last measurable concentration.</description>
          <population>The PK parameter analysis set was defined as all subjects randomized and treated who completed the study.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUClast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.14" spread="33.96"/>
                    <measurement group_id="O2" value="127.36" spread="40.91"/>
                    <measurement group_id="O3" value="121.05" spread="33.76"/>
                    <measurement group_id="O4" value="118.27" spread="29.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUCinf</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.87" spread="43.20"/>
                    <measurement group_id="O2" value="145.22" spread="49.19"/>
                    <measurement group_id="O3" value="140.41" spread="42.18"/>
                    <measurement group_id="O4" value="138.14" spread="34.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Elimination Phase Rate Constant (Kel)</title>
        <description>Estimated as the absolute value of the slope of a linear regression during the terminal phase of the natural-logarithm (ln) transformed concentration-time profile.</description>
        <time_frame>prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose</time_frame>
        <population>The PK parameter analysis set was defined as all subjects randomized and treated who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: 3rd OD Tablet (Test) With Water</title>
            <description>Cohort I: One 5 mg amlodipine 3rd OD tablet (test) taken with water as a single oral dose</description>
          </group>
          <group group_id="O2">
            <title>Cohort I: 2nd OD Tablet (Reference) With Water</title>
            <description>Cohort I: One 5 mg amlodipine 2nd OD tablet (reference) taken with water as a single oral dose</description>
          </group>
          <group group_id="O3">
            <title>Cohort II: 3rd OD Tablet (Test) Without Water</title>
            <description>Cohort II: One 5 mg amlodipine 3rd OD tablet (test) taken without water as a single oral dose</description>
          </group>
          <group group_id="O4">
            <title>Cohort II: 2nd OD Tablet (Reference) Without Water</title>
            <description>Cohort II: One 5 mg amlodipine 2nd OD tablet (reference) taken without water as a single oral dose</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Elimination Phase Rate Constant (Kel)</title>
          <description>Estimated as the absolute value of the slope of a linear regression during the terminal phase of the natural-logarithm (ln) transformed concentration-time profile.</description>
          <population>The PK parameter analysis set was defined as all subjects randomized and treated who completed the study.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0174" spread="0.0031"/>
                    <measurement group_id="O2" value="0.0179" spread="0.0035"/>
                    <measurement group_id="O3" value="0.0162" spread="0.0041"/>
                    <measurement group_id="O4" value="0.0156" spread="0.0031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Elimination Half-Life (T-half)</title>
        <description>Terminal phase half-life calculated as ln(2) / kel</description>
        <time_frame>prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose</time_frame>
        <population>The PK parameter analysis set was defined as all subjects randomized and treated who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: 3rd OD Tablet (Test) With Water</title>
            <description>Cohort I: One 5 mg amlodipine 3rd OD tablet (test) taken with water as a single oral dose</description>
          </group>
          <group group_id="O2">
            <title>Cohort I: 2nd OD Tablet (Reference) With Water</title>
            <description>Cohort I: One 5 mg amlodipine 2nd OD tablet (reference) taken with water as a single oral dose</description>
          </group>
          <group group_id="O3">
            <title>Cohort II: 3rd OD Tablet (Test) Without Water</title>
            <description>Cohort II: One 5 mg amlodipine 3rd OD tablet (test) taken without water as a single oral dose</description>
          </group>
          <group group_id="O4">
            <title>Cohort II: 2nd OD Tablet (Reference) Without Water</title>
            <description>Cohort II: One 5 mg amlodipine 2nd OD tablet (reference) taken without water as a single oral dose</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Elimination Half-Life (T-half)</title>
          <description>Terminal phase half-life calculated as ln(2) / kel</description>
          <population>The PK parameter analysis set was defined as all subjects randomized and treated who completed the study.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.45" spread="9.76"/>
                    <measurement group_id="O2" value="40.27" spread="8.48"/>
                    <measurement group_id="O3" value="45.04" spread="10.16"/>
                    <measurement group_id="O4" value="46.20" spread="8.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Residence Time (MRT)</title>
        <description>MRT = AUMCinf / AUCinf, where AUMCinf is the area under the first moment curve from zero time to infinity calculated as AUMCinf = AUMCt + ((t x Ct) / kel) + (Ct / kel^2). AUMCt is the area under the first moment curve from zero time to time t calculated using the trapezoidal method.</description>
        <time_frame>prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose</time_frame>
        <population>The PK parameter analysis set was defined as all subjects randomized and treated who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: 3rd OD Tablet (Test) With Water</title>
            <description>Cohort I: One 5 mg amlodipine 3rd OD tablet (test) taken with water as a single oral dose</description>
          </group>
          <group group_id="O2">
            <title>Cohort I: 2nd OD Tablet (Reference) With Water</title>
            <description>Cohort I: One 5 mg amlodipine 2nd OD tablet (reference) taken with water as a single oral dose</description>
          </group>
          <group group_id="O3">
            <title>Cohort II: 3rd OD Tablet (Test) Without Water</title>
            <description>Cohort II: One 5 mg amlodipine 3rd OD tablet (test) taken without water as a single oral dose</description>
          </group>
          <group group_id="O4">
            <title>Cohort II: 2nd OD Tablet (Reference) Without Water</title>
            <description>Cohort II: One 5 mg amlodipine 2nd OD tablet (reference) taken without water as a single oral dose</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time (MRT)</title>
          <description>MRT = AUMCinf / AUCinf, where AUMCinf is the area under the first moment curve from zero time to infinity calculated as AUMCinf = AUMCt + ((t x Ct) / kel) + (Ct / kel^2). AUMCt is the area under the first moment curve from zero time to time t calculated using the trapezoidal method.</description>
          <population>The PK parameter analysis set was defined as all subjects randomized and treated who completed the study.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.29" spread="13.55"/>
                    <measurement group_id="O2" value="59.77" spread="11.99"/>
                    <measurement group_id="O3" value="66.18" spread="14.10"/>
                    <measurement group_id="O4" value="67.33" spread="11.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax)</title>
        <time_frame>prior to dosing, 2, 4, 6, 8, 10, 12, 16, 24, 48, 72, 96, 120 and 144 hours post dose</time_frame>
        <population>The PK parameter analysis set was defined as all subjects randomized and treated who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort I: 3rd OD Tablet (Test) With Water</title>
            <description>Cohort I: One 5 mg amlodipine 3rd OD tablet (test) taken with water as a single oral dose</description>
          </group>
          <group group_id="O2">
            <title>Cohort I: 2nd OD Tablet (Reference) With Water</title>
            <description>Cohort I: One 5 mg amlodipine 2nd OD tablet (reference) taken with water as a single oral dose</description>
          </group>
          <group group_id="O3">
            <title>Cohort II: 3rd OD Tablet (Test) Without Water</title>
            <description>Cohort II: One 5 mg amlodipine 3rd OD tablet (test) taken without water as a single oral dose</description>
          </group>
          <group group_id="O4">
            <title>Cohort II: 2nd OD Tablet (Reference) Without Water</title>
            <description>Cohort II: One 5 mg amlodipine 2nd OD tablet (reference) taken without water as a single oral dose</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax)</title>
          <population>The PK parameter analysis set was defined as all subjects randomized and treated who completed the study.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="4" upper_limit="12"/>
                    <measurement group_id="O2" value="8" lower_limit="4" upper_limit="12"/>
                    <measurement group_id="O3" value="8" lower_limit="6" upper_limit="12"/>
                    <measurement group_id="O4" value="8" lower_limit="6" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort I: 3rd OD Tablet (Test) With Water</title>
          <description>Cohort I: One 5 mg amlodipine 3rd OD tablet (test) taken with water as a single oral dose</description>
        </group>
        <group group_id="E2">
          <title>Cohort I: 2nd OD Tablet (Reference) With Water</title>
          <description>Cohort I: One 5 mg amlodipine 2nd OD tablet (reference) taken with water as a single oral dose</description>
        </group>
        <group group_id="E3">
          <title>Cohort II: 3rd OD Tablet (Test) Without Water</title>
          <description>Cohort II: One 5 mg amlodipine 3rd OD tablet (test) taken without water as a single oral dose</description>
        </group>
        <group group_id="E4">
          <title>Cohort II: 2nd OD Tablet (Reference) Without Water</title>
          <description>Cohort II: One 5 mg amlodipine 2nd OD tablet (reference) taken without water as a single oral dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharingitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal disconfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

